Arterra Bioscience S.p.A. (BIT: ARBS)
Italy
· Delayed Price · Currency is EUR 1.930
-0.090 (-4.46%)
Nov 15, 2024, 5:29 PM CET
Arterra Bioscience Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Operating Revenue | 3.96 | 3.3 | 3.56 | 3.83 | 2.82 | 2.71 | Upgrade
|
| Other Revenue | -0.32 | 0.03 | 0.03 | 0.92 | 1.35 | 0.8 | Upgrade
|
| Revenue | 3.64 | 3.34 | 3.59 | 4.74 | 4.17 | 3.51 | Upgrade
|
| Revenue Growth (YoY) | -19.85% | -7.10% | -24.27% | 13.64% | 18.97% | 43.10% | Upgrade
|
| Cost of Revenue | 1.62 | 1.49 | 1.15 | 1.44 | 1.26 | 1.06 | Upgrade
|
| Gross Profit | 2.03 | 1.85 | 2.44 | 3.3 | 2.91 | 2.44 | Upgrade
|
| Selling, General & Admin | 1.62 | 1.56 | 1.47 | 1.39 | 1.28 | 1.17 | Upgrade
|
| Other Operating Expenses | -1.3 | -1.3 | -1.16 | 0.18 | 0.03 | 0.04 | Upgrade
|
| Operating Expenses | 0.75 | 0.79 | 0.84 | 2.06 | 1.71 | 1.51 | Upgrade
|
| Operating Income | 1.28 | 1.06 | 1.6 | 1.25 | 1.2 | 0.94 | Upgrade
|
| Interest Expense | -0 | -0 | -0.01 | -0.01 | -0.02 | -0.01 | Upgrade
|
| Interest & Investment Income | 0.25 | 0.25 | 0.2 | - | - | - | Upgrade
|
| Earnings From Equity Investments | - | - | - | 0 | 0.01 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.14 | -0.01 | 0 | 0.03 | 0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | 1.67 | 1.3 | 1.8 | 1.27 | 1.2 | 0.94 | Upgrade
|
| Pretax Income | 1.67 | 1.3 | 1.8 | 1.27 | 1.2 | 0.94 | Upgrade
|
| Income Tax Expense | 0.32 | 0.23 | 0.38 | 0.16 | 0.09 | 0.08 | Upgrade
|
| Net Income | 1.34 | 1.08 | 1.41 | 1.11 | 1.11 | 0.86 | Upgrade
|
| Net Income to Common | 1.34 | 1.08 | 1.41 | 1.11 | 1.11 | 0.86 | Upgrade
|
| Net Income Growth | 36.67% | -23.89% | 27.33% | 0.17% | 29.32% | -17.90% | Upgrade
|
| Shares Outstanding (Basic) | - | 7 | - | - | - | 7 | Upgrade
|
| Shares Outstanding (Diluted) | - | 7 | - | - | - | 7 | Upgrade
|
| Shares Change (YoY) | - | - | - | - | - | 30.67% | Upgrade
|
| EPS (Basic) | - | 0.16 | - | - | - | 0.13 | Upgrade
|
| EPS (Diluted) | - | 0.16 | - | - | - | 0.13 | Upgrade
|
| EPS Growth | - | - | - | - | - | -37.17% | Upgrade
|
| Free Cash Flow | - | 0.96 | 1.3 | 0.86 | 0.14 | 0.89 | Upgrade
|
| Free Cash Flow Per Share | - | 0.14 | - | - | - | 0.14 | Upgrade
|
| Dividend Per Share | - | 0.100 | 0.100 | 0.050 | - | - | Upgrade
|
| Dividend Growth | - | 0% | 100.00% | - | - | - | Upgrade
|
| Gross Margin | 55.64% | 55.46% | 68.03% | 69.69% | 69.74% | 69.70% | Upgrade
|
| Operating Margin | 35.18% | 31.75% | 44.57% | 26.32% | 28.79% | 26.79% | Upgrade
|
| Profit Margin | 36.90% | 32.26% | 39.38% | 23.42% | 26.57% | 24.44% | Upgrade
|
| Free Cash Flow Margin | - | 28.77% | 36.23% | 18.05% | 3.30% | 25.39% | Upgrade
|
| EBITDA | 1.81 | 1.59 | 2.13 | 1.74 | 1.6 | 1.24 | Upgrade
|
| EBITDA Margin | 49.79% | 47.70% | 59.38% | 36.60% | 38.39% | 35.23% | Upgrade
|
| D&A For EBITDA | 0.53 | 0.53 | 0.53 | 0.49 | 0.4 | 0.3 | Upgrade
|
| EBIT | 1.28 | 1.06 | 1.6 | 1.25 | 1.2 | 0.94 | Upgrade
|
| EBIT Margin | 35.18% | 31.75% | 44.57% | 26.32% | 28.79% | 26.79% | Upgrade
|
| Effective Tax Rate | 19.46% | 17.36% | 21.33% | 12.82% | 7.56% | 8.85% | Upgrade
|
| Revenue as Reported | 5.15 | 4.95 | 5.3 | 4.61 | 4.31 | 3.63 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.